Oxford Biomedica Seeks Block Listing on London Stock Exchange

Oxford BioMedica ( (GB:OXB) ) has issued an announcement.

Oxford Biomedica has applied for a block listing of 250,000 ordinary shares on the London Stock Exchange, as part of its Long Term Incentive Plan. This move is expected to enhance the company’s market presence and provide additional capital for its operations, reinforcing its position as a leader in the cell and gene therapy industry.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on GB:OXB Stock

According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.

Oxford BioMedica’s overall score reflects strong revenue growth and positive strategic developments, tempered by profitability and cash flow challenges. Technical indicators suggest bullish momentum, but valuation metrics indicate ongoing financial pressures.

To see Spark’s full report on GB:OXB stock, click here.

More about Oxford BioMedica

OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vectors, collaborating with leading pharmaceutical and biotechnology firms to provide expertise in lentivirus, adeno-associated virus, adenovirus, and other viral vector types. OXB’s capabilities extend from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise. The company is headquartered in Oxford, UK, with facilities in the UK, France, and the US.

Average Trading Volume: 244,043

Technical Sentiment Signal: Sell

Current Market Cap: £346.4M

See more data about OXB stock on TipRanks’ Stock Analysis page.